Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Frank Clyburn to Board of Directors

Kailera Therapeutics appoints 30-year biopharma industry veteran Frank Clyburn, Jr to its Board of Directors
October 21, 2025 07:00 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

Hengrui Pharma and Kailera today announced an oral presentation of HRS9531 Phase 3 data at ObesityWeek® 2025, the annual meeting of the Obesity Society.
October 14, 2025 06:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity

Kailera Therapeutics announced a $600M Series B financing led by new investor Bain Capital Private Equity to support its late-stage obesity portfolio.
January 27, 2025 07:45 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

Kailera Therapeutics today announced the appointment of Jamie Coleman, former U.S. Brand Leader for Zepbound, as Chief Commercial Officer.
January 13, 2025 08:00 ET | Source: Kailera Therapeutics, Inc.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531

Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.
January 06, 2025 08:15 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.